Your session is about to expire
← Back to Search
JNJ-77242113 for Plaque Psoriasis
Study Summary
This trial aims to determine how well JNJ-77242113 works in people with moderate to severe plaque psoriasis, compared to a placebo and deucravacitinib.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current number of individuals being recruited for participation in this clinical study?
"To conduct this research, a total of 750 eligible individuals who meet the specified inclusion criteria are required. Participants may enroll in this clinical study from multiple locations including Tokyo Medical University Hospital in Tokyo, Florida and Dawes Fretzin Clinical Research Group, LLC in Indianapolis, Ohio."
Are participants currently being enrolled for this study?
"Indeed, according to the details provided on clinicaltrials.gov, this research study is actively seeking eligible candidates. The initial posting of the clinical trial was made on February 5th, 2024 and it underwent its most recent update on January 31st, 2024. A total of 750 participants are being sought from a pool of potential enrollees across 51 different locations."
What are the potential risks associated with JNJ-77242113 when administered to individuals?
"JNJ-77242113 is rated as a 3 on the safety scale by our team at Power, given that this trial is in Phase 3 and has evidence supporting its effectiveness, along with multiple rounds of data confirming its safety."
Can you confirm if there is a significant number of medical facilities conducting this clinical study within the United States?
"This clinical trial is being conducted at Tokyo Medical University Hospital in Tokyo, Florida, Dawes Fretzin Clinical Research Group, LLC in Indianapolis, Ohio, and Forcare Clinical Research, Inc. in Tampa, South dakota. Additionally, there are 51 other locations where the study is taking place."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger